Predictive Oncology (POAI) 10-Q 8 Jun 20 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2020	Jun. 05, 2020
Document Information [Line Items]
Entity Registrant Name	Predictive Oncology Inc.
Entity Central Index Key	0001446159
Trading Symbol	poai
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		10,648,195
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.01 par value

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and Cash Equivalents	$ 3,056,243	$ 150,831
Accounts Receivable	269,777	297,055
Inventories	155,683	190,156
Prepaid Expense and Other Assets	262,470	160,222
Total Current Assets	3,744,173	798,264
Fixed Assets, net	1,377,724	1,507,799
Total, Net Carrying Amount	3,605,417	3,649,412
Lease Right-of-Use Assets	631,392	729,745
Goodwill	15,690,290	15,690,290
Total Assets	25,048,996	22,375,510
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	3,128,520	3,155,641
Notes Payable – Net of Discounts of $493,490 and $350,426	3,817,176	4,795,800
Accrued Expenses	2,142,591	2,371,633
Derivative Liability	2,814,798	50,989
Deferred Revenue	44,129	40,384
Lease Liability – Net of Long-term Portion	427,211	459,481
Total Current Liabilities	12,374,425	10,873,928
Notes Payable, net of current portion	2,115,000
Lease Liability	204,181	270,264
Total Liabilities	14,693,606	11,144,192
Stockholders’ Equity:
Common Stock, $.01 par value, 100,000,000 shares authorized, 5,852,718 and 4,056,652 outstanding	58,527	40,567
Additional paid-in capital	97,289,097	93,653,667
Accumulated Deficit	(87,028,028)	(82,498,711)
Total Stockholders' Equity	10,355,390	11,231,318
Total Liabilities and Stockholders' Equity	25,048,996	22,375,510
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock	792	792
Series D Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock	35,000	35,000
Series E Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock	$ 2	$ 3

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Discount of note payable	$ 493,490	$ 350,426
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares outstanding (in shares)	5,852,718	4,056,652
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	2,300,000	2,300,000
Preferred stock, shares outstanding (in shares)	79,246	79,246
Series D Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	3,500,000	3,500,000
Preferred stock, shares outstanding (in shares)	3,500,000	3,500,000
Series E Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	350	350
Preferred stock, shares outstanding (in shares)	208	285

Condensed Consolidated Statemen

Condensed Consolidated Statements of Net Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue	$ 294,943	$ 255,241
Cost of goods sold	92,657	73,717
Gross margin	202,286	181,524
General and administrative expense	2,828,476	1,497,945
Operations expense	548,753	466,566
Sales and marketing expense	264,409	554,216
Total operating loss	(3,439,352)	(2,337,203)
Other income	27,110	53,432
Other expense	(1,117,075)	(569,776)
Loss on equity method investment		(439,637)
Net loss	$ (4,529,317)	$ (3,293,184)
Loss per common share - basic and diluted (in dollars per share)	$ (0.93)	$ (2.09)
Weighted average shares used in computation - basic and diluted (in shares)	4,866,328	1,573,152

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Series B Convertible Preferred Stock [Member]Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]Preferred Stock [Member]	Series E Convertible Preferred Stock [Member]Preferred Stock [Member]Conversion of Series E Preferred Stock [Member]	Series E Convertible Preferred Stock [Member]Preferred Stock [Member]	Common Stock [Member]Chief Executive Officer [Member]	Common Stock [Member]Promissory Note [Member]	Common Stock [Member]Bridge Notes [Member]	Common Stock [Member]Private Placement [Member]	Common Stock [Member]Equity Line Purchase Agreement [Member]	Common Stock [Member]Conversion of Series E Preferred Stock [Member]	Common Stock [Member]Consultant [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]Chief Executive Officer [Member]	Additional Paid-in Capital [Member]Promissory Note [Member]	Additional Paid-in Capital [Member]Bridge Notes [Member]	Additional Paid-in Capital [Member]Private Placement [Member]	Additional Paid-in Capital [Member]Equity Line Purchase Agreement [Member]	Additional Paid-in Capital [Member]Warrants Issued to CEO [Member]	Additional Paid-in Capital [Member]Warrants Issued Pursuant to 2020 Convertible Debt [Member]	Additional Paid-in Capital [Member]Conversion of Series E Preferred Stock [Member]	Additional Paid-in Capital [Member]Consultant [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Chief Executive Officer [Member]	Promissory Note [Member]	Bridge Notes [Member]	Private Placement [Member]	Equity Line Purchase Agreement [Member]	Warrants Issued to CEO [Member]	Warrants Issued Pursuant to 2020 Convertible Debt [Member]	Consultant [Member]	Total
Balance (in shares) at Dec. 31, 2018	79,246											1,409,175
Balance at Dec. 31, 2018	$ 792											$ 14,092										$ 63,146,533	$ (63,107,945)									$ 53,472
Investment by CEO (in shares)					7,813			286,375
Investment by CEO					$ 78			$ 2,864					$ 49,922			$ 2,426,845								$ 50,000			$ 2,429,709
Shares issued in forbearance agreement (in shares)												16,667
Shares issued in forbearance agreement												$ 166										158,184										158,350
Shares issued pursuant to note conversions - bridge loan (in shares)							15,985
Shares issued pursuant to note conversions - bridge loan							$ 160								$ 89,840											$ 90,000
Warrants issued pursuant to CEO note payable																		$ 318,058											$ 318,058
Vesting expense																						263,600										263,600
Net loss																							(3,293,184)									(3,293,184)
Balance (in shares) at Mar. 31, 2019	79,246											1,736,015
Balance at Mar. 31, 2019	$ 792											$ 17,360										66,452,982	(66,401,129)									70,005
Shares issued pursuant to CEO exchange agreement (in shares)
Balance (in shares) at Dec. 31, 2019	79,246	3,500,000		258								4,056,652
Balance at Dec. 31, 2019	$ 792	$ 35,000		$ 3								$ 40,567										93,653,667	(82,498,711)									11,231,318
Investment by CEO (in shares)									943,000																			943,000
Investment by CEO									$ 9,430								$ 1,860,469											$ 1,869,899
Shares issued pursuant to note conversions - bridge loan (in shares)							170,000
Shares issued pursuant to note conversions - bridge loan			$ (1)				$ 1,700			$ 1,412					$ 265,628					$ (1,411)						$ 267,328
Warrants issued pursuant to CEO note payable																			$ 116,951											$ 116,951
Vesting expense																						287,838										287,838
Net loss																							(4,529,317)									(4,529,317)
Balance (in shares) at Mar. 31, 2020	79,246	3,500,000		208								5,852,718
Balance at Mar. 31, 2020	$ 792	$ 35,000		$ 2								$ 58,527										97,289,097	$ (87,028,028)									10,355,390
Shares issued pursuant to CEO exchange agreement (in shares)					50,000																			130,000
Shares issued pursuant to CEO exchange agreement					$ 500								$ 129,500											$ 130,000
Inducement shares issued pursuant to promissory note extension (in shares)						30,000
Inducement shares issued pursuant to promissory note extension						$ 300								$ 40,950											$ 41,250
Issuance of shares and prefunded warrants pursuant to March 2020 private placement (in shares)								260,000
Issuance of shares and prefunded warrants pursuant to March 2020 private placement								$ 2,600								$ 455,223											$ 457,823
Inducement shares issued pursuant to 2020 convertible debt and warrants (in shares)												46,875
Inducement shares issued pursuant to 2020 convertible debt and warrants												$ 468										$ 119,532										$ 120,000
Shares issued pursuant to series E preferred stock conversions (in shares)			(50)							141,191
Shares issued to consultant and other (in shares)											155,000
Shares issued to consultant and other											$ 1,550										$ 360,750										$ 362,300

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flow from operating activities:
Net loss	$ (4,529,317)	$ (3,293,184)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on equity method investment		439,637
Depreciation and amortization	206,580	39,526
Vesting expense	287,838	263,600
Common stock issued for management and consulting services	362,300
Amortization of debt discount	448,026	468,564
Loss (gain) on valuation of equity-linked instruments and derivative liability	(27,107)	19,408
Debt extinguishment costs	300,000
Equity instruments issued in connection with 2020 convertible debt	16,716
Changes in assets and liabilities:
Accounts receivable	27,278	59,159
Inventories	34,473	(47,957)
Prepaid expense and other assets	(62,248)	(3,273)
Accounts payable	(27,121)	(13,491)
Accrued expenses	(14,144)	21,494
Deferred revenue	3,745	(2,136)
Net cash used in operating activities	(2,972,981)	(2,048,653)
Cash flow from investing activities:
Advance on notes receivable		(631,316)
Transfer of fixed assets to inventory		9,863
Acquisition of intangibles	(32,510)	(3,198)
Net cash used in investing activities:	(32,510)	(624,651)
Cash flow from financing activities:
Extinguishment of convertible debt		(93,827)
Proceeds from debt issuance	1,820,000	1,250,000
Repayment of debt	(821,916)
Payment penalties	(84,898)
Proceeds from issuance of common stock pursuant to equity line	1,869,899
Issuance of common stock, A, B and prefunded warrants, net	3,127,818	2,479,709
Net cash provided by financing activities	5,910,903	3,635,882
Net increase in cash and cash equivalents	2,905,412	962,578
Cash at beginning of period	150,831	162,152
Cash at end of period	3,056,243	1,124,730
Non-cash transactions:
Bridge loan conversion into common stock	267,328	90,000
Inducement shares issued pursuant to convertible debt	103,284
Inducement shares issued for debt extension	41,250
Warrants issued pursuant to debt issuance	116,951
Put and conversion derivative from debt issuance	120,921
Forbearance settlement bridge loan		503,009
Additional warrants issued pursuant to CEO note payable		8,665
Series E Convertible Preferred Stock [Member]
Non-cash transactions:
Series E preferred stock conversions	$ 1,412
Chief Executive Officer [Member]
Non-cash transactions:
Shares issued pursuant to CEO exchange agreement (in shares)	130,000

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 Nature of Operations and Continuance of Operations Predictive Oncology Inc. (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. June 10, 2019, June 13, 2019. October 28, 2019, one ten October 29, 2019. The Company is a healthcare company that provides personalized medicine solutions and medical devices in two 1 2 In addition, the Company’s wholly-owned subsidiary, TumorGenesis Inc. (“TumorGenesis”), is developing the next generation, patient-derived tumor models for precision cancer therapy and drug development. TumorGenesis is presented as part of the condensed consolidated financial statements and is included in corporate in the Company’s segment reporting. During the first 2018, 25% April 4, 2019, 75% The Company has incurred recurring losses from operations and has an accumulated deficit of $87,028,028. not 2019 first 2020, no may $3,056,243 March 31, 2020 $7,788,706 March 31, 2020, six may October 2019, $15,000,000 three no three first 2020, $5,910,903, not one not Coronavirus Outbreak In March 2020, 19 not 19 19 may not no 19 may Interim Financial Statements The Company has prepared the condensed consolidated financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim condensed consolidated financial statements. These interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations, and its cash flows for the interim periods. These interim condensed consolidated financial statements reflect all intercompany eliminations. These interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto contained in the Annual Report on Form 10 April 1, 2020. may not Accounting Policies and Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements during the reporting period. Actual results could materially differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist of cash on hand. The Company had no March 31, 2020 December 31, 2019. Fair Value Measurements As outlined in Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 820, Fair Value Measurement 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities, which consist of cash and cash equivalents, was determined based on Level 1 3 Note 6 Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first first Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements (1) 5 Manufacturing tooling 3 - 7 Demo equipment 3 Laboratory equipment 4 ( 1 Leasehold improvements are depreciated over the shorter of the useful life or the remaining lease term. Upon retirement or sale of fixed assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred. Intangible Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, and customer relationships, and are amortized over their estimated useful life. The tradename is an indefinite-lived intangible asset and is not The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360 Property, Plant and Equipment may not may not not 350— Intangibles—Goodwill and Other not December 31, 2019 $770,250 no March 31, 2020. Goodwill In accordance with ASC 350 Intangibles – Goodwill and Other not Goodwill is not first not may first December 31, 2019 $8,100,000 March 31, 2020, $1,930,101 March 31, 2020, not not Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected an accounting policy to exclude sales taxes from revenue and expenses and to recognize shipping and handling costs at point of sale. The Company has elected a practical expedient and does not one Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within both the domestic and international revenue segments. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company Sales Agreement, and Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer’s contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: ( 1 2 3 4 may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. This revenue stream is reported under the domestic and international sales segments. Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current product sales contracts do not Warranty The Company generally provides one no not Revenue from Clinical Testing The Precision Oncology Insights are clinic diagnostic testing comprised of the Company’s ChemoFx and BioSpeciFx tests. The ChemoFx test determines how a patient’s tumor specimen reacts to a panel of various chemotherapy drugs, while the BioSpeciFx test evaluates the expression of a particular gene related to a patient’s tumor specimen. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Helomics payments terms vary by the agreements reached with insurance carriers and Medicare. The Company’s performance obligations are satisfied at a point in time when test reports are delivered. For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more or less consideration than it originally estimated for a contract with a patient, it will account for the change as an increase or decrease to the estimate of the transaction price, provided that such adjustment does not The Company recognizes revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers 30 CRO Revenue Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company’s efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on the basis of the standalone selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of March 31, 2020, December 31, 2019, $269,777 $297,055, The Company’s deferred revenues related primarily to maintenance plans as of March 31, 2020 December 31, 2019 $44,129 $40,384, Valuation and accounting for stock options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. The fair value of each option grant is estimated on the grant date using the Black-Scholes option valuation model with the following assumptions: Three Months Ended March 31, 2020 2019 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 82.6% 79.8% Risk-free interest rate 0.70% - 1.57% 2.41% - 2.76% Expected life (years) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 82.6% 79.8% Risk-free interest rate 0.54% - 0.79% 2.50% - 2.58% Expected life (years) 2 - 5.5 5 Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no During 2020 2019, 382 may may not 382 Tax years subsequent to 2016 Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred. Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $2,744,429 Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not Acquisition activities Proposed Acquisition of Quantitative Medicine On January 24, 2020, second 2020, Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not not no In June 2016, 2016 13, not 12b 2 1934, January 1, 2023.

Note 2 - Notes Receivable

Note 2 - Notes Receivable	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 2 The Company has a secured promissory note receivable from CytoBioscience for $1,112,524, 8% February 28, 2020. 2019, first April 2019. not first 2019. 2019, On March 2, 2020, not 125,000 May 27, 2020. Note 11

Note 3 - Inventories

Note 3 - Inventories	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 3 Inventory balances are as follows: March 31, December 31, Finished goods $ 61,805 $ 91,410 Raw materials 60,335 69,821 Work-In-Process 33,543 28,925 Total $ 155,683 $ 190,156

Note 4 - Fixed Assets

Note 4 - Fixed Assets	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 The Company’s fixed assets consist of the following: March 31, December 31, Computers and office equipment $ 508,143 $ 508,143 Leasehold improvements 188,014 188,014 Manufacturing tooling 1,510,165 1,510,165 Demo equipment 73,051 73,051 Total 2,279,373 2,279,373 Less: Accumulated depreciation 901,649 771,574 Total Fixed Assets, Net $ 1,377,724 $ 1,507,799 Depreciation expense was $130,075 $21,882 three March 31, 2020 2019,

Note 5 - Intangible Assets

Note 5 - Intangible Assets	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 5 The components of intangible assets were as follows: March 31, 2020 December 31, 2019 Gross Carrying Costs Accumulated Amortization Net Carrying Amount Gross Carrying Costs Accumulated Amortization Net Carrying Amount Patents & Trademarks $ 371,533 $ (198,686 ) $ 172,847 $ 339,023 $ (195,286 ) $ 143,737 Developed Technology 2,882,000 (144,097 ) 2,737,903 2,882,000 (108,075 ) 2,773,925 Customer Relationships 445,000 (148,333 ) 296,667 445,000 (111,250 ) 333,750 Tradename 398,000 - 398,000 398,000 - 398,000 Total $ 4,096,533 $ (491,116 ) $ 3,605,417 $ 4,064,023 $ (414,611 ) $ 3,649,412 Amortization expense was $76,505 $17,644 three March 31, 2020 2019, The following table outlines the estimated future amortization expense related to intangible assets held as of March 31, 2020: Year ending December 31, Expense 2020 $ 231,151 2021 308,201 2022 196,951 2023 159,868 2024 159,868 Thereafter 2,151,378 Total $ 3,207,417

Note 6 - Notes Payable

Note 6 - Notes Payable	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Convertible Debt and Derivative Liability [Text Block]	NOTE 6 The balances of notes payable were as follows: Due Date March 31, 2020 December 31, 2019 Bridge loan June 28, 2020 $ 1,721,776 $ 1,989,104 Promissory note 2019 June 27, 2020 980,833 680,833 Promissory note 2020 T1 August 5, 2020 490,000 - Promissory note 2020 T2 September 5, 2020 480,000 - Short term borrowing May 26, 2020 - 18,563 Short term borrowing June 10, 2020 - 147,783 Short term borrowing June 20, 2020 - 194,943 Short term borrowing August 12, 2020 196,478 - Short term borrowing August 25, 2020 215,526 - Short term borrowing September 11, 2020 226,053 - Dr. Schwartz notes September 30, 2020 2,115,000 2,115,000 Total Notes Payable, gross 6,425,666 5,146,226 Less: Unamortized discount 493,490 350,426 Total Notes Payable, net $ 5,932,176 $ 4,795,800 Bridge Loan In September 2018, two $2,297,727 $2,000,000. 65,000 107,178 $11.55 8% February 2019, $344,659 16,667 September 2019, one March 19, 2020, June 28, 2020. No three March 31, 2020 $430,444 not March 31, 2020. March 31, 2020 $1,721,776, $93,374. Each investor received the right to convert all or any part of its bridge loan into shares of the Company’s common stock at a conversion factor that is the lesser of a discounted 20 may 1 2 267,833 March 31, 2020, no first three 2020 2019, $267,328 $90,000, 170,000 15,985 Dr. Schwartz Notes In November 2018, $370,000. December 31, 2018, one $370,000 $63,028. November 30, 2018 July 15, 2019, $1,920,000 two 22,129 $8.36 February 1, 2019 first October 2019, not During January 2020, two $2,115,000 12% September 30, 2020 50,000 no December 31, 2019. March 31, 2020, $2,115,000. Effective April 21, 2020, March 31, 2020. Note 11 Promissory Note 2019 During September 2019, $847,500 $700,000. 8,857 68,237 $6.21 sixth fifth 8% On March 19, 2020, March 27, 2020 March 31, 2020 June 27, 2020. $300,000 30,000 10% 470, Debt first 2020, $300,000 No three March 31, 2020 $196,167 not March 31, 2020. March 31, 2020, $980,833 $35,750. Promissory Note 2020 On February 5, 2020, $1,450,000 $1,200,000. three $400,000 third February 5, 2020, March 5, 2020, April 5, 2020, 8% $2.589. No three March 31, 2020 $194,000 not March 31, 2020. March 31, 2020, $970,000 $364,366. As additional consideration, the Company issued to the investor warrants to purchase 94,631 92,700 first second 92,700 third sixth $2.992 46,875 first Short Term Borrowings The Company entered into short-term borrowings with an investor. The maturity date of the notes is six 8% three March 31, 2020, $1,098,684 $1,020,000 $821,816 $84,898 three March 31, 2020 $160,380 not March 31, 2020. March 31, 2020 $638,057. Derivative Liabilities Management concluded the September 2018 20 three March 31, 2020, $50,989 $19,408 three March 31, 2020 March 31, 2019, zero March 31, 2020 $50,989 December 31, 2019. On May 21, 2019, February 1, 2019 first 5,753 2019. $22,644 zero December 31, 2019, January 2020, Management concluded the Promissory Note 2020 815, Derivatives and Hedging two $68,796 $52,125 first second three March 31, 2020, March 31, 2020, $17,256 $17,824 first second Management concluded the A, B and agent warrants issued in connection with the March 2020 $2,669,995. March 31, 2020, $2,779,718 $109,723 three March 31, 2020. The table below discloses changes in value of the Company’s embedded derivative liabilities: Derivative liability balance at December 31, 2019 $ 50,989 Derivative instrument recognized for A, B and Agent Warrants 2,669,995 Derivative instrument related to Promissory Note 2020 120,921 Gain recognized to revalue derivative instrument at fair value (27,107) Derivative liability balance at March 31, 2020 $ 2,814,798 Other expense Other expense consisted primarily of interest expense, payment penalties, amortization of original issue discounts, and loss on debt extinguishment related to our notes payable. The Company recognized other expense of $1,117,075 three March 31, 2020 $569,776 2019.

Note 7 - Stockholders' Equity,

Note 7 - Stockholders' Equity, Stock Options and Warrants	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 7 , STOCK OPTIONS AND WARRANTS Series D Preferred Stock In April 2019, 3,500,000 10:1 1 50% 2 one April 4, 2020, 3,500,000 350,004 Series E Convertible Preferred Stock In June September 2019, 258 0.056857% six June 13, 2019. 12 $289,935, December 13, 2019. three March 31, 2020, 50 141,191 Equity Line On October 24, 2019, $15,000,000 three 104,651 $450,000 three may three March 31, 2020, 943,000 $1,869,899 March 31, 2020, $12,810,907 March 2020 In March 2020, 260,000 $2.12 1 one five one 2 one two $1.88 In addition, and in lieu of common shares, the investors also purchased prefunded warrants to purchase 1,390,166 $2.12 $0.0001 Note 8 The sale of the offering shares, prefunded warrants and A and B warrants resulted in gross proceeds of $3,498,612 $3,127,818 March 18, 2020, Note 6 Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2018 366,928 $ 17.03 362,664 $ 41.67 Issued 423,295 6.53 1,869,299 9.25 Forfeited (23,799 ) 13.30 (653 ) 3,249.28 Exercised - - (59,700 ) 0.10 Outstanding at December 31, 2019 766,424 $ 11.34 2,171,610 $ 15.26 Issued 38,350 2.37 5,001,591 1.42 Forfeited (10,736 ) 9.20 (119,441 ) 6.47 Exercised - - - - Outstanding at March 31, 2020 794,038 $ 10.90 7,053,760 $ 4.57 Stock-based compensation expense recognized for the three March 31, 2020 March 31, 2019 $287,838 $263,600, $110,628 18

Note 8 - Loss Per Share

Note 8 - Loss Per Share	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 8 The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended March 31, 2020 2019 Numerator: Net loss attributable to common shareholders per common share: basic and diluted calculation $ (4,529,317 ) $ (3,293,184 ) Denominator: Weighted average common shares outstanding-basic (1) 4,886,328 1,573,152 Effect of diluted stock options, warrants and preferred stock (2) - - Weighted average common shares outstanding-diluted 4,886,328 1,573,152 Loss per common share-basic and diluted $ (0.93 ) $ (2.09 ) ( 1 Includes 1,390,166 three March 31, 2020. ( 2 The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Three Months Ended March 31, 2020 2019 Options 794,038 407,158 Warrants 5,663,594 595,113 Convertible debt 378,000 504,770 Preferred stock: series B 7,925 7,925 Preferred stock: series D 350,000 - Preferred stock: series E 691,159 -

Note 9 - Segments

Note 9 - Segments	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	NOTE 9 The Company has determined its operating segments in accordance with ASC 280 Segment Reporting The Company has three 1 three March 31, 2020 Three Months Ended March 31, 2020 Domestic International Helomics Corporate Total Revenue $ 279,813 - $ 15,130 - $ 294,943 Segment Loss $ (340,779 ) $ (69,065 ) $ (1,412,465 ) $ (2,707,008 ) $ (4,529,317 ) In the first 2019, March 31, 2020 Domestic International Helomics Corporate Total Assets $ 823,804 $ 287,606 $ 21,390,191 $ 2,547,396 $ 25,048,996 December 31, 2019 Domestic International Helomics Corporate Total Assets $ 670,841 $ 298,952 $ 21,275,306 $ 130,411 $ 22,375,510

Note 10 - Related Party Transac

Note 10 - Related Party Transactions	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 10 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). The Company and GLG have a partnership agreement for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women’s cancer. There has been no Richard L. Gabriel is also contracted as the Chief Operating Officer for TumorGenesis. Through April 1, 2019, $12,000 six May 1, 2019, one three $13,500 Dr. Carl Schwartz, the Company’s CEO, made loans to the Company in exchange for promissory notes and common stock. See Note 6

Note 11 - Subsequent Events

Note 11 - Subsequent Events	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 11 – SUBSEQUENT EVENTS Acquisition from Soluble Therapeutics and BioDtech On May 27, 2020, not 125,000 Schwartz Note Exchange Effective as of April 21, 2020, January 31, 2020 $2,115,000. twelve 12% September 30, 2020. April 21, 2020 $77,878, $2,192,878 Dr. Schwartz and the Company agreed to exchange the note for newly issued shares of common stock of the Company at market value. Pursuant to the exchange agreement, Dr. Schwartz was issued 1,533,481 $1.43 April 21, 2020. 1 not 766,740 three 2 not 766,741 six April 2020 On April 20, 2020, $541,867 2 1% 6 60 Pursuant to the terms of the PPP, the promissory note, or a portion thereof, may no may May 2020 During May 2020, 1,396,826 $0.01 1,396,826 $1.575 $1.45 five one $2,200,001 $1,930,101 May 8, 2020. Conversion of Series D Preferred Shares During April 2019, 3,500,000 10:1 April 4, 2020, 3,500,000 350,004 Pending Conversion of Series E Preferred Shares In May 2020, June 13, 2020 207.7 0.056857% 207.7 June 13, 2020, 11.8092% June 12, 2020. Licensing and Collaboration using NSP- 10 The Company entered into a licensing arrangement for a novel nanoparticle vaccine platform recently developed by Dr. Daniel Carter. The vaccine technology being developed by Dr. Carter is based on a self-assembling nanoparticle called NSP- 10 10 February 2020. 1 one Newly formed subsidiaries The Company formed Extraordinary Vaccine Development Corporation as a wholly owned subsidiary in May 2020. 10 The Company also formed Soluble Biotech Inc. as a wholly owned subsidiary in May 2020. May 2020. The Company has evaluated all of its activities and concluded that no

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Nature of Operations and Continuance of Operations Predictive Oncology Inc. (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. June 10, 2019, June 13, 2019. October 28, 2019, one ten October 29, 2019. The Company is a healthcare company that provides personalized medicine solutions and medical devices in two 1 2 In addition, the Company’s wholly-owned subsidiary, TumorGenesis Inc. (“TumorGenesis”), is developing the next generation, patient-derived tumor models for precision cancer therapy and drug development. TumorGenesis is presented as part of the condensed consolidated financial statements and is included in corporate in the Company’s segment reporting. During the first 2018, 25% April 4, 2019, 75% The Company has incurred recurring losses from operations and has an accumulated deficit of $87,028,028. not 2019 first 2020, no may $3,056,243 March 31, 2020 $7,788,706 March 31, 2020, six may October 2019, $15,000,000 three no three first 2020, $5,910,903, not one not
Effect of Covid-19 Pandemic [Policy Text Block]	Coronavirus Outbreak In March 2020, 19 not 19 19 may not no 19 may
Interim Financial Statements, Policy [Policy Text Block]	Interim Financial Statements The Company has prepared the condensed consolidated financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim condensed consolidated financial statements. These interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations, and its cash flows for the interim periods. These interim condensed consolidated financial statements reflect all intercompany eliminations. These interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto contained in the Annual Report on Form 10 April 1, 2020. may not
Use of Estimates, Policy [Policy Text Block]	Accounting Policies and Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements during the reporting period. Actual results could materially differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents consist of cash on hand. The Company had no March 31, 2020 December 31, 2019.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements As outlined in Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 820, Fair Value Measurement 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities, which consist of cash and cash equivalents, was determined based on Level 1 3 Note 6
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first first
Property, Plant and Equipment, Policy [Policy Text Block]	Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements (1) 5 Manufacturing tooling 3 - 7 Demo equipment 3 Laboratory equipment 4 ( 1 Leasehold improvements are depreciated over the shorter of the useful life or the remaining lease term. Upon retirement or sale of fixed assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, and customer relationships, and are amortized over their estimated useful life. The tradename is an indefinite-lived intangible asset and is not The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360 Property, Plant and Equipment may not may not not 350— Intangibles—Goodwill and Other not December 31, 2019 $770,250 no March 31, 2020.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill In accordance with ASC 350 Intangibles – Goodwill and Other not Goodwill is not first not may first December 31, 2019 $8,100,000 March 31, 2020, $1,930,101 March 31, 2020, not not
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected an accounting policy to exclude sales taxes from revenue and expenses and to recognize shipping and handling costs at point of sale. The Company has elected a practical expedient and does not one Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within both the domestic and international revenue segments. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company Sales Agreement, and Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer’s contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: ( 1 2 3 4 may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. This revenue stream is reported under the domestic and international sales segments. Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current product sales contracts do not Warranty The Company generally provides one no not Revenue from Clinical Testing The Precision Oncology Insights are clinic diagnostic testing comprised of the Company’s ChemoFx and BioSpeciFx tests. The ChemoFx test determines how a patient’s tumor specimen reacts to a panel of various chemotherapy drugs, while the BioSpeciFx test evaluates the expression of a particular gene related to a patient’s tumor specimen. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Helomics payments terms vary by the agreements reached with insurance carriers and Medicare. The Company’s performance obligations are satisfied at a point in time when test reports are delivered. For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more or less consideration than it originally estimated for a contract with a patient, it will account for the change as an increase or decrease to the estimate of the transaction price, provided that such adjustment does not The Company recognizes revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers 30 CRO Revenue Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company’s efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on the basis of the standalone selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of March 31, 2020, December 31, 2019, $269,777 $297,055, The Company’s deferred revenues related primarily to maintenance plans as of March 31, 2020 December 31, 2019 $44,129 $40,384,
Valuation and Accounting for Stock Options and Warrants, Policy [Policy Text Block]	Valuation and accounting for stock options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. The fair value of each option grant is estimated on the grant date using the Black-Scholes option valuation model with the following assumptions: Three Months Ended March 31, 2020 2019 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 82.6% 79.8% Risk-free interest rate 0.70% - 1.57% 2.41% - 2.76% Expected life (years) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 82.6% 79.8% Risk-free interest rate 0.54% - 0.79% 2.50% - 2.58% Expected life (years) 2 - 5.5 5
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no During 2020 2019, 382 may may not 382 Tax years subsequent to 2016
Offering Costs [Policy Text Block]	Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $2,744,429
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not
Business Combinations Policy [Policy Text Block]	Acquisition activities Proposed Acquisition of Quantitative Medicine On January 24, 2020, second 2020,
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not not no In June 2016, 2016 13, not 12b 2 1934, January 1, 2023.

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Property Plant and Equipment Useful Life [Table Text Block]	Years Computers and office equipment 3 - 7 Leasehold improvements (1) 5 Manufacturing tooling 3 - 7 Demo equipment 3 Laboratory equipment 4
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Three Months Ended March 31, 2020 2019 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 82.6% 79.8% Risk-free interest rate 0.70% - 1.57% 2.41% - 2.76% Expected life (years) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 82.6% 79.8% Risk-free interest rate 0.54% - 0.79% 2.50% - 2.58% Expected life (years) 2 - 5.5 5

Note 3 - Inventories (Tables)

Note 3 - Inventories (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, December 31, Finished goods $ 61,805 $ 91,410 Raw materials 60,335 69,821 Work-In-Process 33,543 28,925 Total $ 155,683 $ 190,156

Note 4 - Fixed Assets (Tables)

Note 4 - Fixed Assets (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, December 31, Computers and office equipment $ 508,143 $ 508,143 Leasehold improvements 188,014 188,014 Manufacturing tooling 1,510,165 1,510,165 Demo equipment 73,051 73,051 Total 2,279,373 2,279,373 Less: Accumulated depreciation 901,649 771,574 Total Fixed Assets, Net $ 1,377,724 $ 1,507,799

Note 5 - Intangible Assets (Tab

Note 5 - Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	March 31, 2020 December 31, 2019 Gross Carrying Costs Accumulated Amortization Net Carrying Amount Gross Carrying Costs Accumulated Amortization Net Carrying Amount Patents & Trademarks $ 371,533 $ (198,686 ) $ 172,847 $ 339,023 $ (195,286 ) $ 143,737 Developed Technology 2,882,000 (144,097 ) 2,737,903 2,882,000 (108,075 ) 2,773,925 Customer Relationships 445,000 (148,333 ) 296,667 445,000 (111,250 ) 333,750 Tradename 398,000 - 398,000 398,000 - 398,000 Total $ 4,096,533 $ (491,116 ) $ 3,605,417 $ 4,064,023 $ (414,611 ) $ 3,649,412
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year ending December 31, Expense 2020 $ 231,151 2021 308,201 2022 196,951 2023 159,868 2024 159,868 Thereafter 2,151,378 Total $ 3,207,417

Note 6 - Notes Payable (Tables)

Note 6 - Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Short-term Debt [Table Text Block]	Due Date March 31, 2020 December 31, 2019 Bridge loan June 28, 2020 $ 1,721,776 $ 1,989,104 Promissory note 2019 June 27, 2020 980,833 680,833 Promissory note 2020 T1 August 5, 2020 490,000 - Promissory note 2020 T2 September 5, 2020 480,000 - Short term borrowing May 26, 2020 - 18,563 Short term borrowing June 10, 2020 - 147,783 Short term borrowing June 20, 2020 - 194,943 Short term borrowing August 12, 2020 196,478 - Short term borrowing August 25, 2020 215,526 - Short term borrowing September 11, 2020 226,053 - Dr. Schwartz notes September 30, 2020 2,115,000 2,115,000 Total Notes Payable, gross 6,425,666 5,146,226 Less: Unamortized discount 493,490 350,426 Total Notes Payable, net $ 5,932,176 $ 4,795,800
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Derivative liability balance at December 31, 2019 $ 50,989 Derivative instrument recognized for A, B and Agent Warrants 2,669,995 Derivative instrument related to Promissory Note 2020 120,921 Gain recognized to revalue derivative instrument at fair value (27,107) Derivative liability balance at March 31, 2020 $ 2,814,798

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity, Stock Options and Warrants (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Share-based Payment Arrangement, Activity [Table Text Block]	Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2018 366,928 $ 17.03 362,664 $ 41.67 Issued 423,295 6.53 1,869,299 9.25 Forfeited (23,799 ) 13.30 (653 ) 3,249.28 Exercised - - (59,700 ) 0.10 Outstanding at December 31, 2019 766,424 $ 11.34 2,171,610 $ 15.26 Issued 38,350 2.37 5,001,591 1.42 Forfeited (10,736 ) 9.20 (119,441 ) 6.47 Exercised - - - - Outstanding at March 31, 2020 794,038 $ 10.90 7,053,760 $ 4.57

Note 8 - Loss Per Share (Tables

Note 8 - Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 2020 2019 Numerator: Net loss attributable to common shareholders per common share: basic and diluted calculation $ (4,529,317 ) $ (3,293,184 ) Denominator: Weighted average common shares outstanding-basic (1) 4,886,328 1,573,152 Effect of diluted stock options, warrants and preferred stock (2) - - Weighted average common shares outstanding-diluted 4,886,328 1,573,152 Loss per common share-basic and diluted $ (0.93 ) $ (2.09 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2020 2019 Options 794,038 407,158 Warrants 5,663,594 595,113 Convertible debt 378,000 504,770 Preferred stock: series B 7,925 7,925 Preferred stock: series D 350,000 - Preferred stock: series E 691,159 -

Note 9 - Segments (Tables)

Note 9 - Segments (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended March 31, 2020 Domestic International Helomics Corporate Total Revenue $ 279,813 - $ 15,130 - $ 294,943 Segment Loss $ (340,779 ) $ (69,065 ) $ (1,412,465 ) $ (2,707,008 ) $ (4,529,317 ) March 31, 2020 Domestic International Helomics Corporate Total Assets $ 823,804 $ 287,606 $ 21,390,191 $ 2,547,396 $ 25,048,996 December 31, 2019 Domestic International Helomics Corporate Total Assets $ 670,841 $ 298,952 $ 21,275,306 $ 130,411 $ 22,375,510

Note 1 - Summary of Significa_3

Note 1 - Summary of Significant Accounting Policies (Details Textual)	Oct. 28, 2019	Oct. 24, 2019USD ($)	May 15, 2020USD ($)	Oct. 31, 2019USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)	Apr. 04, 2019	Mar. 31, 2018
Retained Earnings (Accumulated Deficit), Ending Balance					$ (87,028,028)		$ (82,498,711)
Cash and Cash Equivalents, at Carrying Value, Ending Balance					3,056,243		150,831
Long-term Debt, Current Maturities, Total					7,788,706
Proceeds from Debt and Equity Financing, Net					5,910,903
Goodwill, Impairment Loss					0		8,100,000
Proceeds from Issuance of Common Stock					3,127,818	$ 2,479,709
Accounts Receivable, after Allowance for Credit Loss, Total					269,777		297,055
Contract with Customer, Liability, Total					44,129		40,384
Income Tax Expense (Benefit), Total					0
Unrecognized Tax Benefits, Ending Balance					0
Liability for Uncertainty in Income Taxes, Current					$ 0
Open Tax Year					2016 2017 2018 2019
Cash, Uninsured Amount					$ 2,744,429
Licensing Agreements [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total					$ 0		$ 770,250
Equity Line Purchase Agreement [Member]
Issuance or Sale of Equity, Can Be Raised		$ 15,000,000
Equity Line Purchase Agreement [Member] | Investor [Member]
Issuance or Sale of Equity, Can Be Raised				$ 15,000,000
Private Placement [Member] | Subsequent Event [Member]
Proceeds from Issuance of Common Stock			$ 1,930,101
Helomics Holding Corp. [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage									25.00%
Business Acquisition, Percentage of Voting Interests Acquired								75.00%
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10

Note 1 - Summary of Significa_4

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	3 Months Ended
	Mar. 31, 2020
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	5 years	[1]
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Laboratory Equipment [Member]
Property, plant, and equipment, useful life (Year)	4 years
Minimum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Maximum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years
[1]	Leasehold improvements are depreciated over the shorter of the useful life or the remaining lease term.

Note 1 - Summary of Significa_5

Note 1 - Summary of Significant Accounting Policies - Valuation Assumptions (Details)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Expected dividend yield	0.00%	0.00%
Expected stock price volatility	82.60%	79.80%
Expected life (years) (Year)	10 years	10 years
Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0	0
Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	82.6	79.8
Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input		5
Minimum [Member]
Risk-free interest rate	0.70%	2.41%
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.54	2.5
Minimum [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	2
Maximum [Member]
Risk-free interest rate	1.57%	2.76%
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.79	2.58
Maximum [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5.5

Note 2 - Notes Receivable (Deta

Note 2 - Notes Receivable (Details Textual) - USD ($)	1 Months Ended
	May 15, 2020	Mar. 31, 2020
CytoBioscience [Member] | Promissory Notes Receivable [Member]
Financing Receivable, after Allowance for Credit Loss, Total		$ 1,112,524
Notes Receivable, Interest Rate, Stated Percentage		8.00%
InventaBio Tech and its subsidiary Soluble [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, Purchase of Assets (in shares)	125,000

Note 3 - Inventories - Schedule

Note 3 - Inventories - Schedule of Inventory (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Finished goods	$ 61,805	$ 91,410
Raw materials	60,335	69,821
Work-In-Process	33,543	28,925
Total	$ 155,683	$ 190,156

Note 4 - Fixed Assets (Details

Note 4 - Fixed Assets (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Depreciation, Total	$ 130,075	$ 21,882

Note 4 - Fixed Assets - Schedul

Note 4 - Fixed Assets - Schedule of Property, Plant and Equipment (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Property, Plant, and Equipment Gross	$ 2,279,373	$ 2,279,373
Less: Accumulated depreciation	901,649	771,574
Total Fixed Assets, Net	1,377,724	1,507,799
Office Equipment [Member]
Property, Plant, and Equipment Gross	508,143	508,143
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	188,014	188,014
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	1,510,165	1,510,165
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 73,051	$ 73,051

Note 5 - Intangible Assets (Det

Note 5 - Intangible Assets (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Amortization of Intangible Assets, Total	$ 76,505	$ 17,644

Note 5 - Intangible Assets - Co

Note 5 - Intangible Assets - Components of Intangible Assets (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Accumulated Amortization	$ (491,116)	$ (414,611)
Net Carrying Amount	3,207,417
Total, Gross Carrying Costs	4,096,533	4,064,023
Total, Net Carrying Amount	3,605,417	3,649,412
Trade Names [Member]
Tradename	398,000	398,000
Patents and Trademarks [Member]
Gross Carrying Costs	371,533	339,023
Accumulated Amortization	(198,686)	(195,286)
Net Carrying Amount	172,847	143,737
Developed Technology Rights [Member]
Gross Carrying Costs	2,882,000	2,882,000
Accumulated Amortization	(144,097)	(108,075)
Net Carrying Amount	2,737,903	2,773,925
Customer Relationships [Member]
Gross Carrying Costs	445,000	445,000
Accumulated Amortization	(148,333)	(111,250)
Net Carrying Amount	$ 296,667	$ 333,750

Note 5 - Intangible Assets - Es

Note 5 - Intangible Assets - Estimated Future Amortization Expense (Details)	Mar. 31, 2020USD ($)
2020	$ 231,151
2021	308,201
2022	196,951
2023	159,868
2024	159,868
Thereafter	2,151,378
Total	$ 3,207,417

Note 6 - Notes Payable (Details

Note 6 - Notes Payable (Details Textual)	Apr. 05, 2020USD ($)shares	Mar. 19, 2020USD ($)shares	Mar. 05, 2020USD ($)shares	Feb. 05, 2020USD ($)$ / sharesshares	Sep. 27, 2019	Sep. 28, 2018USD ($)$ / sharesshares	Jan. 31, 2020USD ($)shares	Sep. 30, 2019USD ($)$ / sharesshares	Feb. 27, 2019USD ($)shares	Nov. 30, 2018USD ($)	Apr. 05, 2020USD ($)shares	Mar. 03, 2020USD ($)	Mar. 03, 2019USD ($)	Mar. 31, 2020USD ($)shares	Mar. 31, 2019USD ($)shares	Jul. 15, 2019USD ($)$ / sharesshares	Apr. 21, 2020USD ($)	Mar. 18, 2020USD ($)	Dec. 31, 2019USD ($)	May 21, 2019shares	Dec. 31, 2018USD ($)
Debt Instrument, Face Amount														$ 6,425,666					$ 5,146,226
Debt Instrument, Unamortized Discount, Total														493,490					350,426
Gain (Loss) on Extinguishment of Debt, Total														(300,000)
Payments for Penalties														84,898
Derivative Liability, Total														2,814,798					50,989
Other Nonoperating Expense, Total												$ 1,117,075	$ 569,776	1,117,075	569,776
Bridge Loan Warrants [Member]
Derivative Liability, Total														0					50,989
Dr. Schwartz Notes Warrants [Member]
Derivative Liability, Total																			0		$ 22,644
Promissory Note 2020 Conversion Feature, Tranche One [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability														68,796
Promissory Note 2020 Conversion Feature, Tranche Two [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability														52,125
Put Option, Tranche One [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability														17,256
Put Option, Tranche Two [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability														17,824
A, B and Agent Warrants [Member]
Derivative Liability, Total														2,779,718				$ 2,669,995
Gain (Loss) on Derivative Instruments, Net, Pretax, Total														109,723
Other Expense [Member]
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net, Total														$ (19,408)
Investor of Promissory Note [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares				46,875
Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares							50,000
Proceeds from Related Party Debt										$ 370,000						$ 1,920,000
Conversion of Bridge Loan to Common Stock [Member]
Debt Conversion, Original Debt, Amount															$ 90,000
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares														170,000	15,985
Bridge Loan Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares						107,178
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 11.55
Dr. Schwartz Notes Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares																22,129
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																$ 8.36
Warrant for Promissory Notes [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares								68,237
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 6.21
Warrants Issued With Promissory Note, One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares				94,631
Warrants Issued With Promissory Note, Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares			92,700
Warrants Issued With Promissory Note, Three [Member] | Subsequent Event [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	92,700										92,700
Warrants Issued With Promissory Note [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 2.992
Warrants Issued for 2019 Agreement [Member] | Chief Executive Officer [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares																				5,753
Convertible Promissory Note [Member]
Debt Instrument, Face Amount														$ 1,721,776					1,989,104
Dr. Schwartz Note, One [Member]
Debt Instrument, Face Amount																					370,000
Debt Instrument, Unamortized Discount, Total																					$ 63,028
DrSchwartz Notes [Member]
Debt Instrument, Face Amount							$ 2,115,000							2,115,000					$ 2,115,000
Debt Instrument, Interest Rate, Stated Percentage							12.00%
Short-term Debt, Total														2,115,000
DrSchwartz Notes [Member] | Subsequent Event [Member]
Short-term Debt, Total																	$ 2,192,878
Second Promissory Note [Member]
Debt Instrument, Face Amount				$ 1,450,000
Debt Instrument, Interest Rate, Stated Percentage				8.00%
Penalties Accrued														194,000
Debt Instrument, Unamortized Discount, Total														364,366
Short-term Debt, Total														970,000
Proceeds from Short-term Debt, Total			$ 400,000	$ 400,000							$ 1,200,000
Payments for Penalties														0
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares				$ 2.589
Second Promissory Note [Member] | Subsequent Event [Member]
Proceeds from Short-term Debt, Total	$ 400,000
Borrowings Against Equity Line [Member]
Debt Instrument, Face Amount														$ 1,098,684
Debt Instrument, Interest Rate, Stated Percentage														8.00%
Penalties Accrued														$ 160,380
Short-term Debt, Total														638,057
Proceeds from Short-term Debt, Total														1,020,000
Payments for Penalties														84,898
Repayments of Short-term Debt, Total														821,816
Bridge Notes [Member] | Convertible Promissory Note [Member]
Debt Instrument, Face Amount						$ 2,297,727
Proceeds from Notes Payable, Total						$ 2,000,000
Stock Issued During Period, Shares, New Issues (in shares) | shares						65,000			16,667
Debt Instrument, Interest Rate, Stated Percentage						8.00%
Debt Instrument, Increase (Decrease), Net, Total									$ 344,659
Penalties Accrued														430,444
Bridge Loan														1,721,776
Debt Instrument, Unamortized Discount, Total														93,374
Debt Instrument, Convertible, Threshold Trading Days						20
Conversion Shares, Sum of Number of Conversion Shares Plus Inducement Shares (in shares) | shares						267,833
Securities Purchase Agreements [Member] | Promissory Note [Member]
Debt Instrument, Face Amount		$ 300,000						$ 847,500
Stock Issued During Period, Shares, New Issues (in shares) | shares								8,857
Debt Instrument, Interest Rate, Stated Percentage								8.00%
Penalties Accrued														196,167
Debt Instrument, Unamortized Discount, Total														35,750
Debt Instrument, Convertible, Threshold Trading Days					20
Short-term Debt, Total														980,833
Proceeds from Short-term Debt, Total								$ 700,000
Stock Issued During Period, Shares, Extension of Notes Payable (in shares) | shares		30,000
Gain (Loss) on Extinguishment of Debt, Total														300,000
Payments for Penalties														$ 0

Note 6 - Notes Payable - Notes

Note 6 - Notes Payable - Notes Payable (Details) - USD ($)	Mar. 31, 2020	Jan. 31, 2020	Dec. 31, 2019
Notes Payable, Gross	$ 6,425,666		$ 5,146,226
Debt Instrument, Unamortized Discount, Total	493,490		350,426
Notes Payable	5,932,176		4,795,800
Convertible Promissory Note [Member]
Notes Payable, Gross	1,721,776		1,989,104
Promissory Note, One [Member]
Notes Payable, Gross	980,833		680,833
Promissory Note, Two [Member]
Notes Payable, Gross	490,000
Promissory Note, Three [Member]
Notes Payable, Gross	480,000
Borrowings Against Equity Line, One [Member]
Notes Payable, Gross			18,563
Borrowings Against Equity Line, Two [Member]
Notes Payable, Gross			147,783
Borrowings Against Equity Line, Three [Member]
Notes Payable, Gross			194,943
Borrowings Against Equity Line, Four [Member]
Notes Payable, Gross	196,478
Borrowings Against Equity Line, Five [Member]
Notes Payable, Gross	215,526
Borrowings Against Equity Line, Six [Member]
Notes Payable, Gross	226,053
DrSchwartz Notes [Member]
Notes Payable, Gross	$ 2,115,000	$ 2,115,000	$ 2,115,000

Note 6 - Notes Payable - Change

Note 6 - Notes Payable - Change in Fair Value of Derivative Liabilities (Details)	3 Months Ended
	Mar. 31, 2020USD ($)
Derivative liability balance	$ 50,989
Gain recognized to revalue derivative instrument at fair value	(27,107)
Derivative liability balance	2,814,798
A, B and Agent Warrants [Member]
Derivative instrument recognized	2,669,995
Derivative liability balance	2,779,718
Promissory Note 2020 [Member]
Derivative instrument recognized	$ 120,921

Note 7 - Stockholders' Equity_3

Note 7 - Stockholders' Equity, Stock Options and Warrants (Details Textual)	May 08, 2020$ / sharesshares	Apr. 04, 2020shares	Oct. 24, 2019USD ($)shares	Mar. 18, 2020USD ($)$ / sharesshares	Apr. 30, 2019shares	Mar. 31, 2020USD ($)shares	Mar. 31, 2019USD ($)	Sep. 30, 2019USD ($)shares
Share-based Payment Arrangement, Expense | $						$ 287,838	$ 263,600
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $						$ 110,628
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Month)						1 year 180 days
Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)						3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)						10 years
Equity Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)						3 years
Warrants issued with Private Placement, One [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1
Warrants and Rights Outstanding, Term (Year)				5 years 182 days
Warrants issued with Private Placement, Two [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1
Warrants and Rights Outstanding, Term (Year)				2 years
Warrants issued with Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 1.88
Prefunded Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 0.0001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				1,390,166
Price of Warrant (in dollars per share) | $ / shares				$ 2.12
Equity Line Purchase Agreement [Member]
Issuance or Sale of Equity, Can Be Raised | $			$ 15,000,000
Stock Issued During Period, Shares, New Issues (in shares)			104,651			943,000
Stock Issued During Period, Value, New Issues | $			$ 450,000			$ 1,869,899
Sale of Stock, Remaining Available Balance | $						$ 12,810,907
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)				260,000
Stock Issued During Period, Value, New Issues | $							$ 2,429,709
Sale of Stock, Price Per Share (in dollars per share) | $ / shares				$ 2.12
Proceeds from Issuance or Sale of Equity, Total | $				$ 3,498,612
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $				$ 3,127,818
Subsequent Event [Member] | Warrants issued with Private Placement [Member]
Warrants and Rights Outstanding, Term (Year)	5 years 182 days
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 1.45
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,396,826
Subsequent Event [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,396,826
Conversion from Series D Preferred Stock to Common Stock [Member] | Subsequent Event [Member]
Conversion of Stock, Shares Converted (in shares)		3,500,000
Conversion of Stock, Shares Issued (in shares)		350,004
Conversion of Series E Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)						50
Conversion of Stock, Shares Issued (in shares)						141,191
Series D Preferred Stock [Member]
Preferred Stock, Shares Issued, Total (in shares)					3,500,000
Convertible Preferred Stock, Conversion Rate					10
Series E Convertible Preferred Stock [Member]
Convertible Preferred Stock, Conversion Rate								0.00056857
Stock Issued During Period, Shares, Convertible Preferred Shares Issued (in shares)								258
Preferred Stock, Beneficial Conversion Feature | $								$ 289,935

Note 7 - Stockholders' Equity_4

Note 7 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Warrant [Member]
Number of Shares Outstanding (in shares)	2,171,610	362,664
Average Exercise Price Outstanding (in dollars per share)	$ 15.26	$ 41.67
Number of Shares Issued (in shares)	5,001,591	1,869,299
Average Exercise Price Issued (in dollars per share)	$ 1.42	$ 9.25
Number of Shares Forfeited (in shares)	(119,441)	(653)
Average Exercise Price Forfeited (in dollars per share)	$ 6.47	$ 3,249.28
Number of Shares Exercised (in shares)		(59,700)
Average Exercise Price Exercised (in dollars per share)		$ 0.10
Number of Shares Outstanding (in shares)	7,053,760	2,171,610
Average Exercise Price Outstanding (in dollars per share)	$ 4.57	$ 15.26
Share-based Payment Arrangement, Option [Member]
Number of Shares Outstanding (in shares)	766,424	366,928
Average Exercise Price Outstanding (in dollars per share)	$ 11.34	$ 17.03
Number of Shares Issued (in shares)	38,350	423,295
Average Exercise Price Issued (in dollars per share)	$ 2.37	$ 6.53
Number of Shares Forfeited (in shares)	(10,736)	(23,799)
Average Exercise Price Forfeited (in dollars per share)	$ 9.20	$ 13.30
Number of Shares Exercised (in shares)
Average Exercise Price Exercised (in dollars per share)
Average Exercise Price Exercised (in dollars per share)
Number of Shares Outstanding (in shares)	794,038	766,424
Average Exercise Price Outstanding (in dollars per share)	$ 10.90	$ 11.34

Note 8 - Loss Per Share (Detail

Note 8 - Loss Per Share (Details Textual)	3 Months Ended
	Mar. 31, 2020shares
Prefunded Warrant [Member]
Weighted Average Number of Shares, Contingently Issuable (in shares)	1,390,166

Note 8 - Loss Per Share - Share

Note 8 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Net loss attributable to common shareholders per common share: basic and diluted calculation		$ (4,529,317)	$ (3,293,184)
Weighted average common shares outstanding-basic (in shares)	[1]	4,886,328	1,573,152
Effect of diluted stock options, warrants and preferred stock (in shares)	[2]
Weighted average common shares outstanding-diluted (in shares)		4,886,328	1,573,152
Loss per common share-basic and diluted (in dollars per share)		$ (0.93)	$ (2.09)
[1]	Includes 1,390,166 contingently issuable shares related to prefunded warrants for the three months ended March 31, 2020.
[2]	(2) The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Three Months Ended March 31, 2020 2019 Options 794,038 407,158 Warrants 5,663,594 595,113 Convertible debt 378,000 504,770 Preferred stock: series B 7,925 7,925 Preferred stock: series D 350,000 - Preferred stock: series E 691,159 -

Note 8 - Loss Per Share - Antid

Note 8 - Loss Per Share - Antidilutive Securities Excluded from the Diluted Calculations (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)	794,038	407,158
Warrant [Member]
Antidilutive Securities (in shares)	5,663,594	595,113
Convertible Debt Securities [Member]
Antidilutive Securities (in shares)	378,000	504,770
Series B Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	7,925	7,925
Series D Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	350,000
Series E Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	691,159

Note 9 - Segments (Details Text

Note 9 - Segments (Details Textual)	3 Months Ended
	Mar. 31, 2020
Number of Operating Segments	3

Note 9 - Segments - Segments (D

Note 9 - Segments - Segments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Revenue	$ 294,943	$ 255,241
Segment Loss	(4,529,317)	$ (3,293,184)
Assets	25,048,996		$ 22,375,510
Corporate, Non-Segment [Member]
Revenue
Segment Loss	(2,707,008)
Assets	2,547,396		130,411
Domestic [Member] | Operating Segments [Member]
Revenue	279,813
Segment Loss	(340,779)
Assets	823,804		670,841
International [Member] | Operating Segments [Member]
Revenue
Segment Loss	(69,065)
Assets	287,606		298,952
Helomics Segment [Member] | Operating Segments [Member]
Revenue	15,130
Segment Loss	(1,412,465)
Assets	$ 21,390,191		$ 21,275,306

Note 10 - Related Party Trans_2

Note 10 - Related Party Transactions (Details Textual) - USD ($)	May 01, 2019	Apr. 01, 2019
Director [Member]
Related Party Transaction, Monthly Cash Payment	$ 13,500	$ 12,000

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual)	Jun. 13, 2020shares	May 27, 2020shares	May 08, 2020USD ($)$ / sharesshares	Apr. 21, 2020USD ($)$ / sharesshares	Apr. 20, 2020USD ($)	Apr. 04, 2020shares	Mar. 18, 2020USD ($)$ / sharesshares	Apr. 30, 2019shares	Mar. 31, 2020USD ($)$ / shares	Jan. 31, 2020USD ($)	Dec. 31, 2019USD ($)$ / shares
Debt Instrument, Face Amount | $									$ 6,425,666		$ 5,146,226
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares									$ 0.01		$ 0.01
Conversion from Series E Preferred Stock to Common Stock [Member] | Forecast [Member]
Conversion of Stock, Shares Converted (in shares)	207.7
Conversion of Stock, Conversion Percentage	0.05686%
Conversion of Stock, Shares Issued, Percentage of Outstanding Shares	11.8092%
Series D Preferred Stock [Member]
Preferred Stock, Shares Issued, Total (in shares)								3,500,000
Convertible Preferred Stock, Conversion Rate								10
Warrants issued with Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares							$ 1.88
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)							260,000
Proceeds from Issuance or Sale of Equity, Total | $							$ 3,498,612
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $							$ 3,127,818
DrSchwartz Notes [Member]
Debt Instrument, Face Amount | $									$ 2,115,000	$ 2,115,000	$ 2,115,000
Debt Instrument, Interest Rate, Stated Percentage										12.00%
Short-term Debt, Total | $									$ 2,115,000
Subsequent Event [Member]
Proceeds from Paycheck Protection Program Under CARES Act | $					$ 541,867
Subsequent Event [Member] | Conversion from Series D Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)						3,500,000
Conversion of Stock, Shares Issued (in shares)						350,004
Subsequent Event [Member] | Warrants issued with Private Placement [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 1.575
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,396,826
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 1.45
Warrants and Rights Outstanding, Term (Year)			5 years 182 days
Subsequent Event [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			1,396,826
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares			$ 0.01
Subsequent Event [Member] | Registered Direct Offering [Member]
Proceeds from Issuance or Sale of Equity, Total | $			$ 2,200,001
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $			$ 1,930,101
Subsequent Event [Member] | Dr. Schwartz [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares				$ 1.43
Stock Issued, Agreement, Not to be Transferred or Sold For Three Months (in shares)				766,740
Stock Issued, Agreement, Not to be Transferred or Sold for Six Months (in shares)				766,741
Subsequent Event [Member] | Dr. Schwartz [Member] | Conversion of Promissory Note Into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)				1,533,481
Subsequent Event [Member] | DrSchwartz Notes [Member]
Interest Payable | $				$ 77,878
Short-term Debt, Total | $				$ 2,192,878
Acquisition from Soluble Therapeutics and BioDtech [Member] | Subsequent Event [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)		125,000